Prognostic association of double-hit signature (DHITsig) in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Kaplan-Meier curves of the DHITsig-positive (DHITsig-pos) germinal center B-cell-like (GCB-) DLBCL versus DHITsig-negative GCB-DLBCL versus activated B-cell-like (ABC-) DLBCL for disease-specific survival (DSS) in the BC Cancer cohort. *P < .001. HR, hazard ratio. From Ennishi D et al: J Clin Oncol 37 (3), 2019: 190-201. Reprinted with permission. © 2019 American Society of Clinical Oncology. All rights reserved.

Prognostic association of double-hit signature (DHITsig) in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Kaplan-Meier curves of the DHITsig-positive (DHITsig-pos) germinal center B-cell-like (GCB-) DLBCL versus DHITsig-negative GCB-DLBCL versus activated B-cell-like (ABC-) DLBCL for disease-specific survival (DSS) in the BC Cancer cohort. *P < .001. HR, hazard ratio. From Ennishi D et al: J Clin Oncol 37 (3), 2019: 190-201. Reprinted with permission. © 2019 American Society of Clinical Oncology. All rights reserved.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal